title: XPC gene polymorphisms contribute to bladder cancer susceptibility: a meta-analysis.
abstract: Numerous studies have investigated the association between three polymorphisms (Lys939Gln, Ala499Val and PAT-/+) of Xeroderma pigmentosum group C (XPC) gene and bladder cancer susceptibility; however, the findings are inconclusive. In order to acquire a more precise estimation of the relationship, we performed a meta-analysis based on 10 studies including 3,934 cases and 4,269 controls for Lys939Gln, five studies including 2,113 cases and 2,249 controls for Ala499Val, and seven studies including 2,834 cases and 3,048 controls for PAT-/+ polymorphism. We searched publications from EMBASE, MEDLINE, and Chinese Biomedical. We calculated pooled odds ratio (OR) and 95% confidence interval (CI) by using either fixed-effects or random-effects model according to the between-study heterogeneity. We found that all studied polymorphisms were individually associated with increased overall cancer risks, as shown by ORs (95% CIs) below: the Lys939Gln (Gln/Gln vs. Lys/Lys: OR = 1.39, 95% CI = 1.08-1.79; recessive model: OR = 1.42, 95% CI = 1.11-1.83; and allele comparing: OR = 1.12, 95% CI = 1.003-1.24), the Ala499Val (Val/Val vs. Ala/Ala: OR = 1.82, 95% CI = 1.19-2.79; recessive model: OR = 1.70, 95% CI = 1.18-2.46; and allele comparing: OR = 1.23, 95% CI = 1.01-1.50), and the PAT-/+ (+/+ vs. -/-: OR = 1.36, 95% CI = 1.03-1.79 and recessive model: OR = 1.34, 95% CI = 1.06-1.70). Furthermore, stratification analyses demonstrated an increased risk for Asian populations as to the Lys939Gln and PAT-/+ whereas for Caucasian populations as to the Ala499Val polymorphism in the homozygous and recessive models. Despite some limitations, this meta-analysis suggests that XPC polymorphisms are associated with bladder cancer risk, but this association warrants further validation in well-designed studies with large sample sizes.
authors.affiliation: Department of Oncology, First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, 510080, People's Republic of China, mddaiqs@163.com.
authors.forename: Qiang-Sheng
authors.initials: QS
authors.lastname: Dai
authors.forename: Rui-Xi
authors.initials: RX
authors.lastname: Hua
authors.forename: Rui-Fang
authors.initials: RF
authors.lastname: Zeng
authors.forename: Jian-Ting
authors.initials: JT
authors.lastname: Long
authors.forename: Zhen-Wei
authors.initials: ZW
authors.lastname: Peng
mesh_terms: D000483:Alleles; D004268:DNA-Binding Proteins / Q000235:genetics*; D020022:Genetic Predisposition to Disease; D005838:Genotype; D006801:Humans; D016017:Odds Ratio; D011110:Polymorphism, Genetic; D017594:Publication Bias; D012306:Risk; D001749:Urinary Bladder Neoplasms / Q000208:ethnology / Q000235:genetics*
chemical_list: D004268:DNA-Binding Proteins; C086984:XPC protein, human
references.citation: Br J Cancer. 2005 Jun 20;92(12):2262-5
references.pmid: 15886698
references.citation: Nat Rev Cancer. 2001 Oct;1(1):22-33
references.pmid: 11900249
references.citation: Carcinogenesis. 2005 Jul;26(7):1263-71
references.pmid: 15746160
references.citation: Eur J Cancer. 2008 Oct;44(15):2241-53
references.pmid: 18771913
references.citation: Carcinogenesis. 2006 May;27(5):1030-7
references.pmid: 16311243
references.citation: Anticancer Res. 2008 May-Jun;28(3B):1853-6
references.pmid: 18630471
references.citation: Mol Carcinog. 2003 Sep;38(1):1-13
references.pmid: 12949838
references.citation: Carcinogenesis. 2000 Oct;21(10):1821-5
references.pmid: 11023539
references.citation: Int J Cancer. 2006 Jun 15;118(12):3030-44
references.pmid: 16404738
references.citation: Biochimie. 1999 Jan-Feb;81(1-2):39-44
references.pmid: 10214908
references.citation: Mol Cell. 1998 Aug;2(2):223-32
references.pmid: 9734359
references.citation: Cancer Epidemiol Biomarkers Prev. 2002 Dec;11(12):1513-30
references.pmid: 12496039
references.citation: J Natl Cancer Inst. 1959 Apr;22(4):719-48
references.pmid: 13655060
references.citation: Cancer Res. 1998 Feb 15;58(4):604-8
references.pmid: 9485007
references.citation: Control Clin Trials. 1986 Sep;7(3):177-88
references.pmid: 3802833
references.citation: Int Urol Nephrol. 2009 Dec;41(4):855-64
references.pmid: 19350405
references.citation: BMC Cancer. 2011 Mar 22;11:101
references.pmid: 21426550
references.citation: J Hum Genet. 2008;53(1):18-33
references.pmid: 18097734
references.citation: Cancer Epidemiol Biomarkers Prev. 2006 Mar;15(3):536-42
references.pmid: 16537713
references.citation: Mol Cell Biol. 2000 Nov;20(21):7980-90
references.pmid: 11027268
references.citation: CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
references.pmid: 21296855
references.citation: Carcinogenesis. 2007 Mar;28(3):698-703
references.pmid: 17052994
references.citation: Oncol Rep. 2012 Jul;28(1):337-45
references.pmid: 22505326
references.citation: BMJ. 1997 Sep 13;315(7109):629-34
references.pmid: 9310563
references.citation: Am J Hum Genet. 2006 Mar;78(3):464-79
references.pmid: 16465622
references.citation: Cancer Epidemiol Biomarkers Prev. 2006 Dec;15(12):2537-41
references.pmid: 17164382
references.citation: Carcinogenesis. 2004 May;25(5):729-34
references.pmid: 14688016
references.citation: Cancer Res. 2009 Sep 1;69(17):6857-64
references.pmid: 19706757
references.citation: Indian J Hum Genet. 2012 Jan;18(1):47-55
references.pmid: 22754221
references.citation: Eur J Hum Genet. 2008 Jun;16(6):724-34
references.pmid: 18285822
references.citation: Int J Med Sci. 2012;9(6):498-505
references.pmid: 22927776
references.citation: Mutat Res. 2010 Dec 10;694(1-2):39-44
references.pmid: 20887739
references.citation: Pathol Oncol Res. 2011 Dec;17(4):879-86
references.pmid: 21647780
references.citation: J Cancer Res Clin Oncol. 2010 May;136(5):779-86
references.pmid: 19924443